Literature DB >> 3930606

Macrophage activation to kill Leishmania major: activation of macrophages for intracellular destruction of amastigotes can be induced by both recombinant interferon-gamma and non-interferon lymphokines.

C A Nacy, A H Fortier, M S Meltzer, N A Buchmeier, R D Schreiber.   

Abstract

Macrophages treated with lymphokine (LK)-rich culture fluids from antigen- or mitogen-stimulated spleen cells or the hybridoma T cell 24/G1, or murine recombinant interferon-gamma (IFN-gamma) from either transfected monkey kidney cells (cos rIFN-gamma) or bacterial (E. coli) DNA (rIFN-gamma) developed the capacity to kill intracellular amastigotes of Leishmania major. Removal of IFN activity from LK by neutralizing fluid phase monoclonal anti-rIFN-gamma antibody, or by solid phase immunoadsorption, left residual macrophage activation factors that induced approximately 50% of the macrophage anti-leishmanial activity of untreated LK. In contrast, rIFN-gamma subjected to the same antibody treatments lost all capacity to induce this macrophage effector function. These results suggest that the intracellular destruction of amastigotes is regulated by several different factors. One of these factors is clearly IFN-gamma, which is pleiotropic in its effects on macrophage functions. The other non-IFN LK factors are immunochemically unrelated to IFN-gamma, and may regulate macrophage microbicidal activities in a more selective manner.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930606

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Influence of costimulatory molecules on immune response to Leishmania major by human cells in vitro.

Authors:  C I Brodskyn; G K DeKrey; R G Titus
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  An in vitro model for infection with Leishmania major that mimics the immune response in mice.

Authors:  M B Soares; J R David; R G Titus
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Down regulation of macrophage activation in Brugia pahangi-infected jirds (Meriones unguiculatus).

Authors:  C Nasarre; J L Krahenbuhl; T R Klei
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

4.  Proteolytic inactivation of cytokines by Pseudomonas aeruginosa.

Authors:  M Parmely; A Gale; M Clabaugh; R Horvat; W W Zhou
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

5.  Role of endogenous gamma interferon in host response to infection with blood-stage Plasmodium chabaudi AS.

Authors:  M M Stevenson; M F Tam; M Belosevic; P H van der Meide; J E Podoba
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis.

Authors:  A Barral; M Barral-Netto; E C Yong; C E Brownell; D R Twardzik; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

7.  Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells.

Authors:  T R Rhinehart-Jones; A H Fortier; K L Elkins
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules.

Authors:  A H Fortier; T Polsinelli; S J Green; C A Nacy
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

9.  Immune reactivity to fractionated Leishmania aethiopica antigens during active human infection.

Authors:  T Laskay; H G Mariam; T Y Berhane; T E Fehniger; R Kiessling
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

10.  Localization of major histocompatibility complex class II molecules in phagolysosomes of murine macrophages infected with Leishmania amazonensis.

Authors:  J C Antoine; C Jouanne; T Lang; E Prina; C de Chastellier; C Frehel
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.